A Phase 2 interventional study of BMS-986165 Placebo and BMS-986165 Dose A in Active Psoriatic Arthritis, sponsored by Bristol-Myers Squibb. Completed at 94 sites in 9 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-02-15.
Sponsored by Bristol-Myers Squibb · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies in Arthritis, Psoriatic by Bristol-Myers Squibb — 1 open to participants now, 3 under way, 3 of them phase 3. Arthritis, Psoriatic · Bristol-Myers Squibb.
Among the 12 studies in Arthritis, Psoriatic by Bristol-Myers Squibb, this one is one of 3 that started in 2019, is one of 2 in phase 2, and was the 7th registered.
601 studies on the registry are indexed under Arthritis, Psoriatic; 129 are open to participants now.
Browse Arthritis, Psoriatic studies →1 of the 12 studies in Arthritis, Psoriatic by Bristol-Myers Squibb is open now. Recruiting first, the newest first:
Bristol-Myers Squibb
Ages 4–75
Of the 88 Arthritis, Psoriatic studies recruiting now, 53 (60%) set no upper age limit and 26 (30%) stop at 75 or younger; 12 take children under 18; 12 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
First in 2007; this study’s year is marked. 3 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 203 is above the median of 145 across 337 interventional studies indexed under Arthritis, Psoriatic.
Median enrollment 203 across the 9 interventional studies, 38,396 across the 3 observational. Of the 9 that completed or were terminated, 3 (33%) have results posted.
This tab as a report to print or save as PDF → With an account.
Bristol-Myers Squibb is the lead sponsor of 1,561 studies on the registry; 118 are open to participants now.
Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 12 studies in Arthritis, Psoriatic by Bristol-Myers Squibb, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The main purpose of study is to assess the dose-response relationship of BMS-986165 (Dose A or Dose B once daily [QD]) at Week 16 in the treatment of participants with active PsA.
The study is intended to evaluate the safety and efficacy of BMS-986165 Dose A or B once daily (QD) compared with placebo in adults with active PsA. The primary endpoint is american college of rheumatology (ACR) 20 response at Week 16 (Part A).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Other: BMS-986165 Placebo
Drug: BMS-986165 Dose A
Drug: BMS-986165 Dose B
Other: BMS-986165 Placebo · Drug: Ustekinumab
Drug: BMS-986165 Dose A · Other: Ustekinumab Placebo
Drug: BMS-986165 Dose B · Other: Ustekinumab Placebo
Participants will receive BMS-986165 matching placebo QD
Participants will receive BMS-986165 Dose A QD.
Participants will receive BMS-986165 dose B QD.
Participants will receive ustekinumab SQ injection QD.
Participants will receive ustekinumab SQ matching placebo QD
Percentage of Participants Achieving the American College of Rheumatology (ACR) 20 Response at Week 16
A participant is considered an ACR 20 responder if the following three conditions are met: 1) ≥ 20% improvement from baseline in the number of tender joints (68 joint count). 2) ≥ 20% improvement from baseline in the number of swollen joints (66 joint count). 3) ≥ 20% improvement from baseline in at least 3 of the following 5 domains: o Subject Global Assessment of disease activity o Physician Global Assessment of psoriatic arthritis o Subject Global Assessment of pain o Health Assessment Questionnaire-Disability Index (HAQ-DI) o High-sensitivity C-reactive protein (hsCRP)
Time frame: 16 weeks after first dose
Adjusted Change From Baseline in the Health Assessment Questionnaire-Disability Index (HAQ-DI)
The HAQ-DI is measured by the use of a patient-reported outcome measure questionnaire, assessing the degree of difficulty a person has experienced during the past week in 8 domains of daily living activities. Each activity category consists of 2 to 3 questions (total of 20 questions). For reach question the level of activity is scored from 0 to 3, with 0 representing "no difficulty" and 3 as "unable to do". Any activity that requires assistance from another individual or an assistive device adjusts to a minimum score of 2. For each activity category, the highest score reported in the 2 or 3 questions pertinent to that category represents the category score. Scores from the 8 categories are then summed and divided by 8 to generate the final score. The final score can range from 0 (most desirable outcome) to 3 (least desirable outcome). Adjusted change represents a change from baseline based on statistical model.
Time frame: From baseline (day of the first dose) to 16 weeks after first dose
Percentage of Participants Achieving the Psoriasis Area and Severity Index (PASI) 75 Response
The PASI is a measure of the average erythema, induration thickness and scaling of psoriatic skin lesions (each graded on a 0 to 4 scale), weighted by the area of involvement (head, arms, trunk to groin, and legs to top of buttocks). The PASI produces a numeric score that can range from 0 to 72, with higher PASI scores denoting more severe disease activity. The PASI 75 response rate represents the percentage of participants who experienced at least a 75% improvement in PASI score as compared with the baseline value. PASI assessment was performed by trained professionals.
Time frame: 16 weeks after first dose
Adjusted Change From Baseline in the Physical Component Summary (PCS) Score of the Short Form Health Survey-36 (SF-36) Questionnaire
The SF-36 is a patient-reported outcome measure, which includes 36 items in a Likert-type format to measure the following 8 health dimensions over the past week: 1) limitations in physical activities, such as bathing or dressing 2) limitations in social activities because of physical or emotional problems 3) limitations in usual role activities because of physical health problems 4) bodily pain 5) general mental health (psychological distress and well-being) 6) limitations in usual role activities because of emotional problems 7) vitality (energy and fatigue) and 8) general health perceptions. The 8 health dimensions assessed are grouped into 2 main components, physical and mental. Each of the 8 dimensions contribute to both the Physical Component Summary (PCS) score and the Mental Component Summary (MCS) score. PCS and MCS scores range from 0 to 100, with high scores indicating a better health status. Adjusted change represents a change from baseline based on statistical model.
Time frame: From baseline (day of the first dose) to 16 weeks after first dose
Percentage of Participants Achieving the American College of Rheumatology (ACR) 50 Response at Week 16
A participant is considered an ACR 50 responder if the following three conditions are met: 1) ≥ 50% improvement from baseline in the number of tender joints (68 joint count). 2) ≥ 50% improvement from baseline in the number of swollen joints (66 joint count). 3) ≥ 50% improvement from baseline in at least 3 of the following 5 domains: o Subject Global Assessment of disease activity o Physician Global Assessment of psoriatic arthritis o Subject Global Assessment of pain o Health Assessment Questionnaire-Disability Index (HAQ-DI) o High-sensitivity C-reactive protein (hsCRP)
Time frame: 16 weeks after first dose
Percentage of Participants Achieving the American College of Rheumatology (ACR) 70 Response at Week 16
A participant is considered an ACR 70 responder if the following three conditions are met: 1) ≥ 70% improvement from baseline in the number of tender joints (68 joint count). 2) ≥ 70% improvement from baseline in the number of swollen joints (66 joint count). 3) ≥ 70% improvement from baseline in at least 3 of the following 5 domains: o Subject Global Assessment of disease activity o Physician Global Assessment of psoriatic arthritis o Subject Global Assessment of pain o Health Assessment Questionnaire-Disability Index (HAQ-DI) o High-sensitivity C-reactive protein (hsCRP)
Time frame: 16 weeks after first dose
Percentage of Participants Achieving Low Disease Activity According to the Disease Activity Score-28 Using C Reactive Protein (DAS 28 CRP)
A Disease Activity Score (DAS) is a scoring system used to assess disease activity. DAS 28 CRP is a composite outcome measure that assesses: • How many joints in the hands (including metacarpophalangeal and proximal interphalangeal joints, but excluding distal interphalangeal joints), wrists, elbows, shoulders, and knees are swollen and/or tender over a total of 28. • C Reactive Protein (CRP) levels in the blood (as a measure of the degree of inflammation) • Subject Global Assessment of disease activity The results are combined to produce the DAS 28 CRP score, which correlates with the extent of disease activity as follows: • \< 2.6: Disease remission • 2.6 - 3.2: Low disease activity • 3.2 - 5.1: Moderate disease activity • \> 5.1: High disease activity. Only participants with a score \< 3.2 are considered to have achieved low disease activity.
Time frame: 16 weeks after first dose
Percentage of Participants Achieving Remission According to the Disease Activity Score-28 Using C Reactive Protein (DAS 28 CRP)
A Disease Activity Score (DAS) is a scoring system used to assess disease activity. DAS 28 CRP is a composite outcome measure that assesses: • How many joints in the hands (including metacarpophalangeal and proximal interphalangeal joints, but excluding distal interphalangeal joints), wrists, elbows, shoulders, and knees are swollen and/or tender over a total of 28. • C Reactive Protein (CRP) levels in the blood (as a measure of the degree of inflammation) • Subject Global Assessment of disease activity The results are combined to produce the DAS 28 CRP score, which correlates with the extent of disease activity as follows: • \< 2.6: Disease remission • 2.6 - 3.2: Low disease activity • 3.2 - 5.1: Moderate disease activity • \> 5.1: High disease activity. Only participants with a score \< 2.6 are considered to have achieved remission.
Time frame: 16 weeks after first dose
Adjusted Change From Baseline in the Disease Activity Score-28 Using C Reactive Protein (DAS 28 CRP) Score
A Disease Activity Score (DAS) is a scoring system used to assess disease activity. DAS 28 CRP is a composite outcome measure that assesses: • How many joints in the hands (including metacarpophalangeal and proximal interphalangeal joints, but excluding distal interphalangeal joints), wrists, elbows, shoulders, and knees are swollen and/or tender over a total of 28. • C Reactive Protein (CRP) levels in the blood (as a measure of the degree of inflammation) • Subject Global Assessment of disease activity The results are combined to produce the DAS 28 CRP score, which correlates with the extent of disease activity as follows: • \< 2.6: Disease remission • 2.6 - 3.2: Low disease activity • 3.2 - 5.1: Moderate disease activity • \> 5.1: High disease activity. Adjusted change represents a change from baseline based on statistical model.
Time frame: From baseline (day of first dose) to 16 weeks after first dose
Adjusted Change From Baseline in Dactylitis Count
The number of digits in hands and feet with dactylitis (Tender + Non-Tender) was counted and change from baseline at week 16 was assessed. Adjusted change represents a change from baseline based on statistical model.
Time frame: From baseline (day of first dose) to 16 weeks after first dose
Adjusted Change From Baseline in the Leeds Dactylitis Index (LDI) Basic Score
The Leeds Dactylitis Index (LDI) Basic is a quantitative measurement of dactylitis in the 20 digits using a dactylometer. The circumference of the affected and contralateral digits, and tenderness of the affected digits are measured to generate a total score. For each dactylitic digit, the final score is defined as: \[{(A/B) - 1}\*100\]\*C, where A is circumference of involved digit, B is circumference of the opposite, unaffected, digit or reference, and C is tenderness (0 or 1). The total score is determined by summing the relative score of all digits. A higher score indicates worse dactylitis. Adjusted change represents a change from baseline based on statistical model.
Time frame: From baseline (day of first dose) to 16 weeks after first dose
Percentage of Participants Achieving Dactylitis Resolution
Dactylitis resolution (tender digits only) is defined as a dactylitis count of 0 in participants with dactylitis count ≥ 1 at baseline
Time frame: 16 weeks after first dose
Adjusted Change From Baseline in Enthesitis by the Leeds Enthesitis Index (LEI)
The LEI was developed specifically for psoriatic arthritis. An overall score of 0 to 6 is derived from the presence or absence of tenderness at 6 entheseal sites (right and left: lateral epicondyle, medial femoral condyle, and Achilles tendon insertion) at the time of evaluation. A higher count indicates a greater enthesitis burden. Adjusted change represents a change from baseline based on statistical model.
Time frame: From baseline (day of first dose) to 16 weeks after first dose
Adjusted Change From Baseline in Enthesitis by the Spondyloarthritis Research Consortium of Canada (SPARCC) Enthesitis Index
The SPARCC Enthesitis Index has a 0 to 16 score that is derived from the evaluation of 8 locations: the greater trochanter (R/L), quadriceps tendon insertion into the patella (R/L), patellar ligament insertion into the patella and tibial tuberosity (R/L), Achilles tendon insertion (R/L), plantar fascia insertion (R/L), medial and lateral epicondyles (R/L), and the supraspinatus insertion (R/L). A higher count indicates a higher enthesitis burden based on the current evaluation. Adjusted change represents a change from baseline based on statistical model.
Time frame: From baseline (day of first dose) to 16 weeks after first dose
Percentage of Participants Achieving Enthesitis Resolution by the Leeds Enthesitis Index (LEI)
The LEI was developed specifically for psoriatic arthritis. An overall score of 0 to 6 is derived from the presence or absence of tenderness at 6 entheseal sites (right and left: lateral epicondyle, medial femoral condyle, and Achilles tendon insertion) at the time of evaluation. A higher count indicates a greater enthesitis burden. Enthesitis resolution is defined as s LEI score of 0, in subjects with LEI ≥ 1 at baseline
Time frame: 16 weeks after first dose
Percentage of Participants Achieving Enthesitis Resolution by the Spondyloarthritis Research Consortium of Canada (SPARCC) Enthesitis Index
The SPARCC Enthesitis Index has a 0 to 16 score that is derived from the evaluation of 8 locations: the greater trochanter (R/L), quadriceps tendon insertion into the patella (R/L), patellar ligament insertion into the patella and tibial tuberosity (R/L), Achilles tendon insertion (R/L), plantar fascia insertion (R/L), medial and lateral epicondyles (R/L), and the supraspinatus insertion (R/L). A higher count indicates a higher enthesitis burden based on the current evaluation. Enthesitis resolution defined as a SPARCC enthesitis index score of 0, in subjects with SPARCC ≥ 1 at baseline.
Time frame: 16 weeks after first dose
Percentage of Participants Achieving a Physicians Global Assessment-Fingernails (PGA-F) Score of 0 or 1
In participants with psoriasis fingernail involvement, the PGA-F score is used to evaluate the overall condition of the fingernails in terms of disease severity. The assessment is performed by the investigator, who rates the fingernail condition on a 5-point scale based on the higher of the nail bed/nail matrix score. Scores are 0 (clear), 1 (minimal), 2 (mild), 3 (moderate), 4 (severe).
Time frame: 16 weeks after first dose
Percentage of Participants Achieving Minimal Disease Activity (MDA) Response
A Minimal Disease Activity (MDA) responder is defined as a participant fulfilling 5 of the following 7 outcomes: • Tender joint count ≤ 1 • Swollen joint count ≤ 1 • Psoriasis Area and Severity Index (PASI) ≤ 1 or body surface area (BSA) ≤ 3% • Subject Global Assessment of pain ≤ 15 • Subject Global Assessment of disease activity ≤ 20 • Health Assessment Questionnaire-Disability Index (HAQ-DI) ≤ 0.5 • Tender entheseal points ≤ 1
Time frame: 16 weeks after first dose
Adjusted Change From Baseline in the Psoriatic Arthritis Disease Activity Score (PASDAS)
PASDAS is a composite measure calculated from the Physician Global Assessment of psoriatic arthritis, the Subject Global Assessment of disease activity, the Short Form Health Survey-36 Item (SF-36) Physical Component Summary (PCS), the swollen joint count, the tender joint count, the Leeds Enthesitis Index (LEI), the Leeds Dactylitis Index (LDI) (Basic), and the the levels of high-sensitivity C-reactive Protein (hsCRP). Each item contributes differently to the final score, which ranges from 0 to 10 (higher scores represent a higher level of disease activity). Adjusted change represents a change from baseline based on statistical model.
Time frame: From baseline (day of first dose) to 16 weeks after first dose
Adjusted Change From Baseline in the Disease Activity Index for Psoriatic Arthritis Score (DAPSA)
DAPSA is a composite measure to assess peripheral joint involvement that is based upon numerical summation of 5 variables of disease activity: tender/painful joint count 68, swollen joint count 66, Subject Global Assessment of disease activity, Subject Global Assessment of pain, and the levels of C-reactive Protein (CRP). Final scores are interpreted as follows: - ≤4 = Remission (REM) - \> 4 and ≤ 28 = moderate disease activity (MDA) - \>28 = high disease activity (HDA). Adjusted change represents a change from baseline based on statistical model.
Time frame: From baseline (day of first dose) to 16 weeks after first dose
Percentage of Participants Achieving Psoriatic Arthritis Response Criteria (PsARC)
PsARC consists of 4 measurements: tender/painful joint count, swollen joint count, Physician Global Assessment of psoriatic arthritis, and Subject Global Assessment of pain ≤ 15. In order to be classified as a PsARC responder, participants must achieve improvement in 2 of 4 measures, one of which must be joint pain or swelling, without worsening in any measure.
Time frame: 16 weeks after first dose
Adjusted Change From Baseline in the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI)
In participants with baseline evidence of Psoriatic Arthritis Spondylitis, symptoms are evaluated using the BASDAI, which consists of a 0 to 100 scale measuring discomfort, pain, and fatigue in response to 6 questions pertaining to the 5 major symptoms of ankylosing spondylitis: • Fatigue (medical) • Spinal pain • Joint pain and swelling • Areas of localized tenderness • Morning stiffness duration • Morning stiffness severity A higher count indicates worse disease. Adjusted change represents a change from baseline based on statistical model.
Time frame: From baseline (day of first dose) to 16 weeks after first dose
Adjusted Change From Baseline in the Mental Component Summary (MCS) Score of the Short Form Health Survey-36 (SF-36) Questionnaire
The SF-36 is a patient-reported outcome measure, which includes 36 items in a Likert-type format to measure the following 8 health dimensions over the past week: 1) limitations in physical activities, such as bathing or dressing 2) limitations in social activities because of physical or emotional problems 3) limitations in usual role activities because of physical health problems 4) bodily pain 5) general mental health (psychological distress and well-being) 6) limitations in usual role activities because of emotional problems 7) vitality (energy and fatigue) and 8) general health perceptions. The 8 health dimensions assessed are grouped into 2 main components, physical and mental. Each of the 8 dimensions contribute to both the Physical Component Summary (PCS) score and the Mental Component Summary (MCS) score. PCS and MCS scores range from 0 to 100, with high scores indicating a better health status. Adjusted change represents a change from baseline based on statistical model.
Time frame: From baseline (day of the first dose) to 16 weeks after first dose
Adjusted Change From Baseline in the Psoriatic Arthritis Impact of Disease (PsAID) 12 Score
PsAID is a 12-item self-report that measures psoriatic arthritis symptoms and impact of disease. Each item is scored on a 0 to 10 numeric rating scale, and each item contributes differently to the final score. Weighted scores for each item are summed and divided by 20 to generate the final score, ranging from 0 to 10 (higher values indicate worse health). Adjusted change represents a change from baseline based on statistical model.
Time frame: From baseline (day of the first dose) to 16 weeks after first dose
Adjusted Change From Baseline in the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue) Score
The FACIT-Fatigue instrument is a questionnaire used to evaluate a range of self-reported symptoms over the past week, from mild subjective feelings of tiredness to an overwhelming, debilitating, and sustained sense of exhaustion that likely decreases one's ability to execute daily activities and function normally in family or social roles. Fatigue is divided into the experience of fatigue (frequency, duration, and intensity) and the impact of fatigue on physical, mental, and social activities. The questionnaire is composed of 13 questions (Short Form 13a) and each question is scored from 1 to 5. The final score results from the sum of the scores of the 13 questions, and ranges from 13 (most desirable outcome) to 65 (least desirable outcome). Adjusted change represents a change from baseline based on statistical model.
Time frame: From baseline (day of the first dose) to 16 weeks after first dose
Adjusted Change From Baseline in the Work Limitation Questionnaire (WLQ) Score
The Work Limitation Questionnaire (WLQ) is a 25-item self-report that measures the on-the-job impact of chronic health conditions and treatment over the past 2 weeks. It focuses on assessing limitations while performing specific job demands from the following 4 domains: 1) Time management: difficulty with handling time and scheduling demands (5 items) 2) Physical demands: ability to perform job tasks that involve bodily strength, movement, endurance, coordination, and flexibility (6 items) 3) Mental-interpersonal demands: cognitively demanding tasks and on-the-job social interactions (9 items) 4) Output demands: concerns reduced work productivity (5 items). Final score ranges from 0 (limited none of the time) to 100 (limited all of the time). The score can be used to calculate a percent of lost work productivity due to a particular disease state. Adjusted change represents a change from baseline based on statistical model.
Time frame: From baseline (day of the first dose) to 16 weeks after first dose
Percentage of Participants Achieving Health Assessment Questionnaire-Disability Index (HAQ-DI) 0.35 Response
The HAQ-DI is measured by the use of a patient-reported outcome measure questionnaire, assessing the degree of difficulty a person has experienced during the past week in 8 domains of daily living activities: dressing and grooming, arising, eating, walking, hygiene, reach, grip, and other activities. Each activity category consists of 2 to 3 questions (total of 20 questions). For reach question the level of activity is scored from 0 ("no difficulty") to 3 ("unable to do"). For each activity category, the highest score reported in the 2 or 3 questions pertinent to that category represents the category score. Scores from the 8 categories are then summed and divided by 8 to generate the final score. The final score can range from 0 (most desirable outcome) to 3 (least desirable outcome). A HAQ-DI 0.35 responder is defined as a participant with an improvement from baseline in HAQ-DI score of at least 0.35.
Time frame: 16 weeks after first dose
Percentage of Participants Achieving the Psoriasis Area and Severity Index (PASI) 90 Response
The PASI is a measure of the average erythema, induration thickness and scaling of psoriatic skin lesions (each graded on a 0 to 4 scale), weighted by the area of involvement (head, arms, trunk to groin, and legs to top of buttocks). The PASI produces a numeric score that can range from 0 to 72, with higher PASI scores denoting more severe disease activity. The PASI 90 response rate represents the percentage of participants who experienced at least a 90% improvement in PASI score as compared with the baseline value. PASI assessment was performed by trained professionals.
Time frame: 16 weeks after first dose
Change From Baseline in Electrocardiogram (ECG) Results
Time frame: From baseline (day of first dose) to 16 weeks after first dose
Change From Baseline in Electrocardiogram (ECG) Heart Rate
Time frame: From baseline (day of first dose) to 16 weeks after first dose
Change From Baseline in Vital Signs - Diastolic Blood Pressure
Time frame: From baseline (day of first dose) to 16 weeks after first dose
Change From Baseline in Vital Signs - Heart Rate
Time frame: From baseline (day of first dose) to 16 weeks after first dose
Change From Baseline in Vital Signs - Respiratory Rate
Time frame: From baseline (day of first dose) to 16 weeks after first dose
Change From Baseline in Vital Signs - Systolic Blood Pressure
Time frame: From baseline (day of first dose) to 16 weeks after first dose
Change From Baseline in Vital Signs - Temperature
Time frame: From baseline (day of first dose) to 16 weeks after first dose
Change From Baseline in Vital Signs - Weight
Time frame: From baseline (day of first dose) to 16 weeks after first dose
| Milestone | Placebo | BMS-986165 6 mg | BMS-986165 12 mg |
|---|---|---|---|
| Started | 66 | 70 | 67 |
| Completed | 58 | 63 | 59 |
| Not completed | 8 | 7 | 8 |
| Withdrew: Adverse event | 1 | 3 | 4 |
| Withdrew: Randomized by mistake with study treatment | 0 | 1 | 1 |
| Withdrew: Withdrawal by subject | 5 | 2 | 3 |
| Withdrew: Other reasons | 2 | 1 | 0 |
| Milestone | Placebo | BMS-986165 6 mg | BMS-986165 12 mg |
|---|---|---|---|
| Started | 55 | 60 | 58 |
| Participants maintaining same treatment as in part a | 0 | 13 | 16 |
| Participants treated with ustekinumab in part b | 55 | 47 | 42 |
| Completed | 47 | 54 | 47 |
| Not completed | 8 | 6 | 11 |
| Withdrew: Adverse event | 0 | 0 | 3 |
| Withdrew: Death | 0 | 1 | 1 |
| Withdrew: Lack of efficacy | 1 | 1 | 0 |
| Withdrew: Lost to follow-up | 1 | 1 | 0 |
| Withdrew: Site terminated by sponsor | 1 | 0 | 3 |
| Withdrew: Withdrawal by subject | 1 | 0 | 1 |
| Withdrew: Other reasons | 4 | 3 | 3 |
A participant is considered an ACR 20 responder if the following three conditions are met: 1) ≥ 20% improvement from baseline in the number of tender joints (68 joint count). 2) ≥ 20% improvement from baseline in the number of swollen joints (66 joint count). 3) ≥ 20% improvement from baseline in at least 3 of the following 5 domains: o Subject Global Assessment of disease activity o Physician Global Assessment of psoriatic arthritis o Subject Global Assessment of pain o Health Assessment Questionnaire-Disability Index (HAQ-DI) o High-sensitivity C-reactive protein (hsCRP)
| Percent of Participants | Placebo | BMS-986165 6 mg | BMS-986165 12 mg |
|---|---|---|---|
| Percentage of Participants Achieving the American College of Rheumatology (ACR) 20 Response at Week 16 | 31.8 (20.6 to 43.1) | 52.9 (41.2 to 64.6) | 62.7 (51.1 to 74.3) |
The HAQ-DI is measured by the use of a patient-reported outcome measure questionnaire, assessing the degree of difficulty a person has experienced during the past week in 8 domains of daily living activities. Each activity category consists of 2 to 3 questions (total of 20 questions). For reach question the level of activity is scored from 0 to 3, with 0 representing "no difficulty" and 3 as "unable to do". Any activity that requires assistance from another individual or an assistive device adjusts to a minimum score of 2. For each activity category, the highest score reported in the 2 or 3 questions pertinent to that category represents the category score. Scores from the 8 categories are then summed and divided by 8 to generate the final score. The final score can range from 0 (most desirable outcome) to 3 (least desirable outcome). Adjusted change represents a change from baseline based on statistical model.
| Score on a scale | Placebo | BMS-986165 6 mg | BMS-986165 12 mg |
|---|---|---|---|
| Adjusted Change From Baseline in the Health Assessment Questionnaire-Disability Index (HAQ-DI) | -0.11 ± 0.066 | -0.37 ± 0.065 | -0.39 ± 0.067 |
The PASI is a measure of the average erythema, induration thickness and scaling of psoriatic skin lesions (each graded on a 0 to 4 scale), weighted by the area of involvement (head, arms, trunk to groin, and legs to top of buttocks). The PASI produces a numeric score that can range from 0 to 72, with higher PASI scores denoting more severe disease activity. The PASI 75 response rate represents the percentage of participants who experienced at least a 75% improvement in PASI score as compared with the baseline value. PASI assessment was performed by trained professionals.
| Percent of Participants | Placebo | BMS-986165 6 mg | BMS-986165 12 mg |
|---|---|---|---|
| Percentage of Participants Achieving the Psoriasis Area and Severity Index (PASI) 75 Response | 20.4 (9.6 to 31.1) | 42.4 (29.8 to 55.0) | 59.6 (46.3 to 73.0) |
The SF-36 is a patient-reported outcome measure, which includes 36 items in a Likert-type format to measure the following 8 health dimensions over the past week: 1) limitations in physical activities, such as bathing or dressing 2) limitations in social activities because of physical or emotional problems 3) limitations in usual role activities because of physical health problems 4) bodily pain 5) general mental health (psychological distress and well-being) 6) limitations in usual role activities because of emotional problems 7) vitality (energy and fatigue) and 8) general health perceptions. The 8 health dimensions assessed are grouped into 2 main components, physical and mental. Each of the 8 dimensions contribute to both the Physical Component Summary (PCS) score and the Mental Component Summary (MCS) score. PCS and MCS scores range from 0 to 100, with high scores indicating a better health status. Adjusted change represents a change from baseline based on statistical model.
| Score on a scale | Placebo | BMS-986165 6 mg | BMS-986165 12 mg |
|---|---|---|---|
| Adjusted Change From Baseline in the Physical Component Summary (PCS) Score of the Short Form Health Survey-36 (SF-36) Questionnaire | 2.3 ± 0.97 | 5.6 ± 0.94 | 5.8 ± 0.97 |
A participant is considered an ACR 50 responder if the following three conditions are met: 1) ≥ 50% improvement from baseline in the number of tender joints (68 joint count). 2) ≥ 50% improvement from baseline in the number of swollen joints (66 joint count). 3) ≥ 50% improvement from baseline in at least 3 of the following 5 domains: o Subject Global Assessment of disease activity o Physician Global Assessment of psoriatic arthritis o Subject Global Assessment of pain o Health Assessment Questionnaire-Disability Index (HAQ-DI) o High-sensitivity C-reactive protein (hsCRP)
| Percent of Participants | Placebo | BMS-986165 6 mg | BMS-986165 12 mg |
|---|---|---|---|
| Percentage of Participants Achieving the American College of Rheumatology (ACR) 50 Response at Week 16 | 10.6 (3.2 to 18.0) | 24.3 (14.2 to 34.3) | 32.8 (21.6 to 44.1) |
A participant is considered an ACR 70 responder if the following three conditions are met: 1) ≥ 70% improvement from baseline in the number of tender joints (68 joint count). 2) ≥ 70% improvement from baseline in the number of swollen joints (66 joint count). 3) ≥ 70% improvement from baseline in at least 3 of the following 5 domains: o Subject Global Assessment of disease activity o Physician Global Assessment of psoriatic arthritis o Subject Global Assessment of pain o Health Assessment Questionnaire-Disability Index (HAQ-DI) o High-sensitivity C-reactive protein (hsCRP)
| Percent of Participants | Placebo | BMS-986165 6 mg | BMS-986165 12 mg |
|---|---|---|---|
| Percentage of Participants Achieving the American College of Rheumatology (ACR) 70 Response at Week 16 | 1.5 (0.0 to 4.5) | 14.3 (6.1 to 22.5) | 19.4 (9.9 to 28.9) |
A Disease Activity Score (DAS) is a scoring system used to assess disease activity. DAS 28 CRP is a composite outcome measure that assesses: • How many joints in the hands (including metacarpophalangeal and proximal interphalangeal joints, but excluding distal interphalangeal joints), wrists, elbows, shoulders, and knees are swollen and/or tender over a total of 28. • C Reactive Protein (CRP) levels in the blood (as a measure of the degree of inflammation) • Subject Global Assessment of disease activity The results are combined to produce the DAS 28 CRP score, which correlates with the extent of disease activity as follows: • \< 2.6: Disease remission • 2.6 - 3.2: Low disease activity • 3.2 - 5.1: Moderate disease activity • \> 5.1: High disease activity. Only participants with a score \< 3.2 are considered to have achieved low disease activity.
| Percent of Participants | Placebo | BMS-986165 6 mg | BMS-986165 12 mg |
|---|---|---|---|
| Percentage of Participants Achieving Low Disease Activity According to the Disease Activity Score-28 Using C Reactive Protein (DAS 28 CRP) | 22.7 (12.6 to 32.8) | 37.1 (25.8 to 48.5) | 43.3 (31.4 to 55.1) |
A Disease Activity Score (DAS) is a scoring system used to assess disease activity. DAS 28 CRP is a composite outcome measure that assesses: • How many joints in the hands (including metacarpophalangeal and proximal interphalangeal joints, but excluding distal interphalangeal joints), wrists, elbows, shoulders, and knees are swollen and/or tender over a total of 28. • C Reactive Protein (CRP) levels in the blood (as a measure of the degree of inflammation) • Subject Global Assessment of disease activity The results are combined to produce the DAS 28 CRP score, which correlates with the extent of disease activity as follows: • \< 2.6: Disease remission • 2.6 - 3.2: Low disease activity • 3.2 - 5.1: Moderate disease activity • \> 5.1: High disease activity. Only participants with a score \< 2.6 are considered to have achieved remission.
| Percent of Participants | Placebo | BMS-986165 6 mg | BMS-986165 12 mg |
|---|---|---|---|
| Percentage of Participants Achieving Remission According to the Disease Activity Score-28 Using C Reactive Protein (DAS 28 CRP) | 6.1 (0.3 to 11.8) | 24.3 (14.2 to 34.3) | 25.4 (15.0 to 35.8) |
A Disease Activity Score (DAS) is a scoring system used to assess disease activity. DAS 28 CRP is a composite outcome measure that assesses: • How many joints in the hands (including metacarpophalangeal and proximal interphalangeal joints, but excluding distal interphalangeal joints), wrists, elbows, shoulders, and knees are swollen and/or tender over a total of 28. • C Reactive Protein (CRP) levels in the blood (as a measure of the degree of inflammation) • Subject Global Assessment of disease activity The results are combined to produce the DAS 28 CRP score, which correlates with the extent of disease activity as follows: • \< 2.6: Disease remission • 2.6 - 3.2: Low disease activity • 3.2 - 5.1: Moderate disease activity • \> 5.1: High disease activity. Adjusted change represents a change from baseline based on statistical model.
| Score on a scale | Placebo | BMS-986165 6 mg | BMS-986165 12 mg |
|---|---|---|---|
| Adjusted Change From Baseline in the Disease Activity Score-28 Using C Reactive Protein (DAS 28 CRP) Score | -0.9 ± 0.15 | -1.7 ± 0.15 | -1.7 ± 0.15 |
The number of digits in hands and feet with dactylitis (Tender + Non-Tender) was counted and change from baseline at week 16 was assessed. Adjusted change represents a change from baseline based on statistical model.
| Digits with dactylitis | Placebo | BMS-986165 6 mg | BMS-986165 12 mg |
|---|---|---|---|
| Adjusted Change From Baseline in Dactylitis Count | -1.8 ± 0.40 | -2.0 ± 0.38 | -2.5 ± 0.38 |
The Leeds Dactylitis Index (LDI) Basic is a quantitative measurement of dactylitis in the 20 digits using a dactylometer. The circumference of the affected and contralateral digits, and tenderness of the affected digits are measured to generate a total score. For each dactylitic digit, the final score is defined as: \[{(A/B) - 1}\*100\]\*C, where A is circumference of involved digit, B is circumference of the opposite, unaffected, digit or reference, and C is tenderness (0 or 1). The total score is determined by summing the relative score of all digits. A higher score indicates worse dactylitis. Adjusted change represents a change from baseline based on statistical model.
| Score on a scale | Placebo | BMS-986165 6 mg | BMS-986165 12 mg |
|---|---|---|---|
| Adjusted Change From Baseline in the Leeds Dactylitis Index (LDI) Basic Score | -28.3 ± 8.87 | -41.8 ± 8.35 | -44.5 ± 8.90 |
Dactylitis resolution (tender digits only) is defined as a dactylitis count of 0 in participants with dactylitis count ≥ 1 at baseline
| Percent of Participants | Placebo | BMS-986165 6 mg | BMS-986165 12 mg |
|---|---|---|---|
| Percentage of Participants Achieving Dactylitis Resolution | 60.0 (40.8 to 79.2) | 76.7 (61.5 to 91.8) | 79.2 (62.9 to 95.4) |
The LEI was developed specifically for psoriatic arthritis. An overall score of 0 to 6 is derived from the presence or absence of tenderness at 6 entheseal sites (right and left: lateral epicondyle, medial femoral condyle, and Achilles tendon insertion) at the time of evaluation. A higher count indicates a greater enthesitis burden. Adjusted change represents a change from baseline based on statistical model.
| Score on a scale | Placebo | BMS-986165 6 mg | BMS-986165 12 mg |
|---|---|---|---|
| Adjusted Change From Baseline in Enthesitis by the Leeds Enthesitis Index (LEI) | -1.2 ± 0.27 | -1.5 ± 0.25 | -1.7 ± 0.28 |
The SPARCC Enthesitis Index has a 0 to 16 score that is derived from the evaluation of 8 locations: the greater trochanter (R/L), quadriceps tendon insertion into the patella (R/L), patellar ligament insertion into the patella and tibial tuberosity (R/L), Achilles tendon insertion (R/L), plantar fascia insertion (R/L), medial and lateral epicondyles (R/L), and the supraspinatus insertion (R/L). A higher count indicates a higher enthesitis burden based on the current evaluation. Adjusted change represents a change from baseline based on statistical model.
| Score on a scale | Placebo | BMS-986165 6 mg | BMS-986165 12 mg |
|---|---|---|---|
| Adjusted Change From Baseline in Enthesitis by the Spondyloarthritis Research Consortium of Canada (SPARCC) Enthesitis Index | -1.2 ± 0.54 | -2.9 ± 0.48 | -3.1 ± 0.51 |
The LEI was developed specifically for psoriatic arthritis. An overall score of 0 to 6 is derived from the presence or absence of tenderness at 6 entheseal sites (right and left: lateral epicondyle, medial femoral condyle, and Achilles tendon insertion) at the time of evaluation. A higher count indicates a greater enthesitis burden. Enthesitis resolution is defined as s LEI score of 0, in subjects with LEI ≥ 1 at baseline
| Percent of Participants | Placebo | BMS-986165 6 mg | BMS-986165 12 mg |
|---|---|---|---|
| Percentage of Participants Achieving Enthesitis Resolution by the Leeds Enthesitis Index (LEI) | 22.6 (7.9 to 37.3) | 51.3 (35.6 to 67.0) | 50.0 (30.8 to 69.2) |
The SPARCC Enthesitis Index has a 0 to 16 score that is derived from the evaluation of 8 locations: the greater trochanter (R/L), quadriceps tendon insertion into the patella (R/L), patellar ligament insertion into the patella and tibial tuberosity (R/L), Achilles tendon insertion (R/L), plantar fascia insertion (R/L), medial and lateral epicondyles (R/L), and the supraspinatus insertion (R/L). A higher count indicates a higher enthesitis burden based on the current evaluation. Enthesitis resolution defined as a SPARCC enthesitis index score of 0, in subjects with SPARCC ≥ 1 at baseline.
| Percent of Participants | Placebo | BMS-986165 6 mg | BMS-986165 12 mg |
|---|---|---|---|
| Percentage of Participants Achieving Enthesitis Resolution by the Spondyloarthritis Research Consortium of Canada (SPARCC) Enthesitis Index | 17.6 (4.8 to 30.5) | 51.2 (36.2 to 66.1) | 41.2 (24.6 to 57.7) |
In participants with psoriasis fingernail involvement, the PGA-F score is used to evaluate the overall condition of the fingernails in terms of disease severity. The assessment is performed by the investigator, who rates the fingernail condition on a 5-point scale based on the higher of the nail bed/nail matrix score. Scores are 0 (clear), 1 (minimal), 2 (mild), 3 (moderate), 4 (severe).
| Percent of Participants | Placebo | BMS-986165 6 mg | BMS-986165 12 mg |
|---|---|---|---|
| Percentage of Participants Achieving a Physicians Global Assessment-Fingernails (PGA-F) Score of 0 or 1 | 0 (0.0 to 0.0) | 21.4 (0.0 to 42.9) | 50.0 (28.1 to 71.9) |
A Minimal Disease Activity (MDA) responder is defined as a participant fulfilling 5 of the following 7 outcomes: • Tender joint count ≤ 1 • Swollen joint count ≤ 1 • Psoriasis Area and Severity Index (PASI) ≤ 1 or body surface area (BSA) ≤ 3% • Subject Global Assessment of pain ≤ 15 • Subject Global Assessment of disease activity ≤ 20 • Health Assessment Questionnaire-Disability Index (HAQ-DI) ≤ 0.5 • Tender entheseal points ≤ 1
| Percent of Participants | Placebo | BMS-986165 6 mg | BMS-986165 12 mg |
|---|---|---|---|
| Percentage of Participants Achieving Minimal Disease Activity (MDA) Response | 7.6 (1.2 to 14.0) | 22.9 (13.0 to 32.7) | 23.9 (13.7 to 34.1) |
PASDAS is a composite measure calculated from the Physician Global Assessment of psoriatic arthritis, the Subject Global Assessment of disease activity, the Short Form Health Survey-36 Item (SF-36) Physical Component Summary (PCS), the swollen joint count, the tender joint count, the Leeds Enthesitis Index (LEI), the Leeds Dactylitis Index (LDI) (Basic), and the the levels of high-sensitivity C-reactive Protein (hsCRP). Each item contributes differently to the final score, which ranges from 0 to 10 (higher scores represent a higher level of disease activity). Adjusted change represents a change from baseline based on statistical model.
| Score on a scale | Placebo | BMS-986165 6 mg | BMS-986165 12 mg |
|---|---|---|---|
| Adjusted Change From Baseline in the Psoriatic Arthritis Disease Activity Score (PASDAS) | -1.1 ± 0.21 | -2.0 ± 0.20 | -2.1 ± 0.20 |
DAPSA is a composite measure to assess peripheral joint involvement that is based upon numerical summation of 5 variables of disease activity: tender/painful joint count 68, swollen joint count 66, Subject Global Assessment of disease activity, Subject Global Assessment of pain, and the levels of C-reactive Protein (CRP). Final scores are interpreted as follows: - ≤4 = Remission (REM) - \> 4 and ≤ 28 = moderate disease activity (MDA) - \>28 = high disease activity (HDA). Adjusted change represents a change from baseline based on statistical model.
| Score on a scale | Placebo | BMS-986165 6 mg | BMS-986165 12 mg |
|---|---|---|---|
| Adjusted Change From Baseline in the Disease Activity Index for Psoriatic Arthritis Score (DAPSA) | -13.3 ± 2.20 | -23.2 ± 2.16 | -25.6 ± 2.23 |
PsARC consists of 4 measurements: tender/painful joint count, swollen joint count, Physician Global Assessment of psoriatic arthritis, and Subject Global Assessment of pain ≤ 15. In order to be classified as a PsARC responder, participants must achieve improvement in 2 of 4 measures, one of which must be joint pain or swelling, without worsening in any measure.
| Percent of Participants | Placebo | BMS-986165 6 mg | BMS-986165 12 mg |
|---|---|---|---|
| Percentage of Participants Achieving Psoriatic Arthritis Response Criteria (PsARC) | 54.5 (42.5 to 66.6) | 75.7 (65.7 to 85.8) | 74.6 (64.2 to 85.0) |
In participants with baseline evidence of Psoriatic Arthritis Spondylitis, symptoms are evaluated using the BASDAI, which consists of a 0 to 100 scale measuring discomfort, pain, and fatigue in response to 6 questions pertaining to the 5 major symptoms of ankylosing spondylitis: • Fatigue (medical) • Spinal pain • Joint pain and swelling • Areas of localized tenderness • Morning stiffness duration • Morning stiffness severity A higher count indicates worse disease. Adjusted change represents a change from baseline based on statistical model.
| Score on a scale | Placebo | BMS-986165 6 mg | BMS-986165 12 mg |
|---|---|---|---|
| Adjusted Change From Baseline in the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) | -1.7 ± 0.55 | -2.0 ± 0.48 | -2.2 ± 0.57 |
The SF-36 is a patient-reported outcome measure, which includes 36 items in a Likert-type format to measure the following 8 health dimensions over the past week: 1) limitations in physical activities, such as bathing or dressing 2) limitations in social activities because of physical or emotional problems 3) limitations in usual role activities because of physical health problems 4) bodily pain 5) general mental health (psychological distress and well-being) 6) limitations in usual role activities because of emotional problems 7) vitality (energy and fatigue) and 8) general health perceptions. The 8 health dimensions assessed are grouped into 2 main components, physical and mental. Each of the 8 dimensions contribute to both the Physical Component Summary (PCS) score and the Mental Component Summary (MCS) score. PCS and MCS scores range from 0 to 100, with high scores indicating a better health status. Adjusted change represents a change from baseline based on statistical model.
| Score on a scale | Placebo | BMS-986165 6 mg | BMS-986165 12 mg |
|---|---|---|---|
| Adjusted Change From Baseline in the Mental Component Summary (MCS) Score of the Short Form Health Survey-36 (SF-36) Questionnaire | 0.7 ± 1.00 | 3.6 ± 0.97 | 3.5 ± 1.01 |
PsAID is a 12-item self-report that measures psoriatic arthritis symptoms and impact of disease. Each item is scored on a 0 to 10 numeric rating scale, and each item contributes differently to the final score. Weighted scores for each item are summed and divided by 20 to generate the final score, ranging from 0 to 10 (higher values indicate worse health). Adjusted change represents a change from baseline based on statistical model.
| Score on a scale | Placebo | BMS-986165 6 mg | BMS-986165 12 mg |
|---|---|---|---|
| Adjusted Change From Baseline in the Psoriatic Arthritis Impact of Disease (PsAID) 12 Score | -1.0 ± 0.26 | -2.1 ± 0.26 | -2.3 ± 0.26 |
The FACIT-Fatigue instrument is a questionnaire used to evaluate a range of self-reported symptoms over the past week, from mild subjective feelings of tiredness to an overwhelming, debilitating, and sustained sense of exhaustion that likely decreases one's ability to execute daily activities and function normally in family or social roles. Fatigue is divided into the experience of fatigue (frequency, duration, and intensity) and the impact of fatigue on physical, mental, and social activities. The questionnaire is composed of 13 questions (Short Form 13a) and each question is scored from 1 to 5. The final score results from the sum of the scores of the 13 questions, and ranges from 13 (most desirable outcome) to 65 (least desirable outcome). Adjusted change represents a change from baseline based on statistical model.
| Score on a scale | Placebo | BMS-986165 6 mg | BMS-986165 12 mg |
|---|---|---|---|
| Adjusted Change From Baseline in the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue) Score | 2.8 ± 1.17 | 5.6 ± 1.16 | 7.2 ± 1.18 |
The Work Limitation Questionnaire (WLQ) is a 25-item self-report that measures the on-the-job impact of chronic health conditions and treatment over the past 2 weeks. It focuses on assessing limitations while performing specific job demands from the following 4 domains: 1) Time management: difficulty with handling time and scheduling demands (5 items) 2) Physical demands: ability to perform job tasks that involve bodily strength, movement, endurance, coordination, and flexibility (6 items) 3) Mental-interpersonal demands: cognitively demanding tasks and on-the-job social interactions (9 items) 4) Output demands: concerns reduced work productivity (5 items). Final score ranges from 0 (limited none of the time) to 100 (limited all of the time). The score can be used to calculate a percent of lost work productivity due to a particular disease state. Adjusted change represents a change from baseline based on statistical model.
| Score on a scale | Placebo | BMS-986165 6 mg | BMS-986165 12 mg |
|---|---|---|---|
| Adjusted Change From Baseline in the Work Limitation Questionnaire (WLQ) Score | -1.2 ± 0.69 | -1.9 ± 0.67 | -2.7 ± 0.70 |
The HAQ-DI is measured by the use of a patient-reported outcome measure questionnaire, assessing the degree of difficulty a person has experienced during the past week in 8 domains of daily living activities: dressing and grooming, arising, eating, walking, hygiene, reach, grip, and other activities. Each activity category consists of 2 to 3 questions (total of 20 questions). For reach question the level of activity is scored from 0 ("no difficulty") to 3 ("unable to do"). For each activity category, the highest score reported in the 2 or 3 questions pertinent to that category represents the category score. Scores from the 8 categories are then summed and divided by 8 to generate the final score. The final score can range from 0 (most desirable outcome) to 3 (least desirable outcome). A HAQ-DI 0.35 responder is defined as a participant with an improvement from baseline in HAQ-DI score of at least 0.35.
| Percent of Participants | Placebo | BMS-986165 6 mg | BMS-986165 12 mg |
|---|---|---|---|
| Percentage of Participants Achieving Health Assessment Questionnaire-Disability Index (HAQ-DI) 0.35 Response | 15.2 (6.5 to 23.8) | 38.6 (27.2 to 50.0) | 40.3 (28.6 to 52.0) |
The PASI is a measure of the average erythema, induration thickness and scaling of psoriatic skin lesions (each graded on a 0 to 4 scale), weighted by the area of involvement (head, arms, trunk to groin, and legs to top of buttocks). The PASI produces a numeric score that can range from 0 to 72, with higher PASI scores denoting more severe disease activity. The PASI 90 response rate represents the percentage of participants who experienced at least a 90% improvement in PASI score as compared with the baseline value. PASI assessment was performed by trained professionals.
| Percent of Participants | Placebo | BMS-986165 6 mg | BMS-986165 12 mg |
|---|---|---|---|
| Percentage of Participants Achieving the Psoriasis Area and Severity Index (PASI) 90 Response | 9.3 (1.5 to 17.0) | 20.3 (10.1 to 30.6) | 34.6 (21.7 to 47.5) |
| msec | Placebo | BMS-986165 6 mg | BMS-986165 12 mg |
|---|---|---|---|
| PR Interval, Aggregate | 3.9 ± 16.40 | 3.2 ± 17.83 | -2.9 ± 37.09 |
| QRS Duration, Aggregate | -0.5 ± 9.07 | 3.9 ± 11.58 | -1.1 ± 13.55 |
| QT Interval, Aggregate | 1.4 ± 27.47 | 2.7 ± 28.56 | 1.5 ± 26.81 |
| QTcB Interval, Aggregate | 2.8 ± 41.79 | -6.7 ± 24.46 | 0.4 ± 20.34 |
| QTcF Interval, Aggregate | -0.6 ± 29.83 | 2.4 ± 29.62 | 4.4 ± 22.96 |
| beats/min | Placebo | BMS-986165 6 mg | BMS-986165 12 mg |
|---|---|---|---|
| Change From Baseline in Electrocardiogram (ECG) Heart Rate | -0.7 ± 8.28 | -1.0 ± 9.84 | 0.0 ± 8.82 |
| mmHg | Placebo | BMS-986165 6 mg | BMS-986165 12 mg |
|---|---|---|---|
| Change From Baseline in Vital Signs - Diastolic Blood Pressure | 1.1 ± 8.67 | -0.9 ± 6.10 | -1.7 ± 7.06 |
| beats/min | Placebo | BMS-986165 6 mg | BMS-986165 12 mg |
|---|---|---|---|
| Change From Baseline in Vital Signs - Heart Rate | 0.7 ± 9.40 | -2.5 ± 9.02 | 0.8 ± 8.56 |
| breaths/min | Placebo | BMS-986165 6 mg | BMS-986165 12 mg |
|---|---|---|---|
| Change From Baseline in Vital Signs - Respiratory Rate | 0.0 ± 1.88 | -0.2 ± 1.46 | 0.2 ± 1.16 |
| mmHg | Placebo | BMS-986165 6 mg | BMS-986165 12 mg |
|---|---|---|---|
| Change From Baseline in Vital Signs - Systolic Blood Pressure | 1.6 ± 11.05 | -0.6 ± 10.95 | -1.5 ± 11.44 |
| Celsius degree (C) | Placebo | BMS-986165 6 mg | BMS-986165 12 mg |
|---|---|---|---|
| Change From Baseline in Vital Signs - Temperature | -0.05 ± 0.307 | -0.07 ± 0.364 | -0.06 ± 0.323 |
| Kg | Placebo | BMS-986165 6 mg | BMS-986165 12 mg |
|---|---|---|---|
| Change From Baseline in Vital Signs - Weight | -0.24 ± 3.690 | 0.18 ± 2.646 | 0.43 ± 2.823 |
Collected over All-cause mortality was assessed from date of first dose to study completion (up to approximately 21 months). Serious Adverse events and other adverse events were assessed from date of first dose to 30 days following date of last dose (up to approximately 13 months).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Only Part A:Placebo | 0/11 (0%) | 2/11 (18.2%) | 6/11 (54.5%) |
| Only Part A:BMS-986165 6 mg QD | 0/10 (0%) | 0/10 (0%) | 7/10 (70%) |
| Only Part A:BMS-986165 12 mg QD | 0/9 (0%) | 0/9 (0%) | 7/9 (77.8%) |
| Part A: Placebo + Part B: Ustekinumab SQ | 0/55 (0%) | 0/55 (0%) | 34/55 (61.8%) |
| BMS-986165 6 mg in Part A and Part B | 0/13 (0%) | 1/13 (7.7%) | 13/13 (100%) |
| Part A: BMS-986165 6 mg QD - Part B: Ustekinumab SQ | 1/47 (2.1%) | 3/47 (6.4%) | 30/47 (63.8%) |
| BMS-986165 12 mg in Part A and Part B | 0/16 (0%) | 0/16 (0%) | 11/16 (68.8%) |
| Part A: BMS-986165 12 mg QD - Part B: Ustekinumab SQ | 1/42 (2.4%) | 4/42 (9.5%) | 31/42 (73.8%) |
| Event | Only Part A:Placebo | Only Part A:BMS-986165 6 mg QD | Only Part A:BMS-986165 12 mg QD | Part A: Placebo + Part B: Ustekinumab SQ | BMS-986165 6 mg in Part A and Part B | Part A: BMS-986165 6 mg QD - Part B: Ustekinumab SQ | BMS-986165 12 mg in Part A and Part B | Part A: BMS-986165 12 mg QD - Part B: Ustekinumab SQ |
|---|---|---|---|---|---|---|---|---|
| Metastatic carcinoid tumourNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/11 | 0/10 | 0/9 | 0/55 | 0/13 | 0/47 | 0/16 | 0/42 |
| Deep vein thrombosisVascular disorders | 1/11 | 0/10 | 0/9 | 0/55 | 0/13 | 0/47 | 0/16 | 0/42 |
| Psoriatic arthropathyMusculoskeletal and connective tissue disorders | 0/11 | 0/10 | 0/9 | 0/55 | 1/13 | 0/47 | 0/16 | 0/42 |
| Neuropathy peripheralNervous system disorders | 0/11 | 0/10 | 0/9 | 0/55 | 1/13 | 0/47 | 0/16 | 0/42 |
| Atrial fibrillationCardiac disorders | 0/11 | 0/10 | 0/9 | 0/55 | 0/13 | 0/47 | 0/16 | 1/42 |
| PneumoniaInfections and infestations | 0/11 | 0/10 | 0/9 | 0/55 | 0/13 | 0/47 | 0/16 | 1/42 |
| Chest injuryInjury, poisoning and procedural complications | 0/11 | 0/10 | 0/9 | 0/55 | 0/13 | 0/47 | 0/16 | 1/42 |
| Road traffic accidentInjury, poisoning and procedural complications | 0/11 | 0/10 | 0/9 | 0/55 | 0/13 | 0/47 | 0/16 | 1/42 |
| NauseaGastrointestinal disorders | 0/11 | 0/10 | 0/9 | 0/55 | 0/13 | 1/47 | 0/16 | 0/42 |
| DeathGeneral disorders | 0/11 | 0/10 | 0/9 | 0/55 | 0/13 | 1/47 | 0/16 | 0/42 |
| Event | Only Part A:Placebo | Only Part A:BMS-986165 6 mg QD | Only Part A:BMS-986165 12 mg QD | Part A: Placebo + Part B: Ustekinumab SQ | BMS-986165 6 mg in Part A and Part B | Part A: BMS-986165 6 mg QD - Part B: Ustekinumab SQ | BMS-986165 12 mg in Part A and Part B | Part A: BMS-986165 12 mg QD - Part B: Ustekinumab SQ |
|---|---|---|---|---|---|---|---|---|
| NasopharyngitisInfections and infestations | 0/11 | 0/10 | 1/9 | 7/55 | 1/13 | 6/47 | 2/16 | 11/42 |
| PyrexiaGeneral disorders | 0/11 | 1/10 | 0/9 | 0/55 | 1/13 | 0/47 | 3/16 | 1/42 |
| PsoriasisSkin and subcutaneous tissue disorders | 2/11 | 1/10 | 0/9 | 2/55 | 1/13 | 1/47 | 0/16 | 0/42 |
| Upper respiratory tract infectionInfections and infestations | 0/11 | 0/10 | 0/9 | 4/55 | 2/13 | 3/47 | 1/16 | 0/42 |
| Aspartate aminotransferase increasedInvestigations | 0/11 | 0/10 | 0/9 | 1/55 | 2/13 | 0/47 | 1/16 | 2/42 |
| HeadacheNervous system disorders | 1/11 | 1/10 | 1/9 | 6/55 | 2/13 | 6/47 | 0/16 | 1/42 |
| HypertensionVascular disorders | 0/11 | 0/10 | 0/9 | 1/55 | 2/13 | 3/47 | 0/16 | 0/42 |
| PharyngitisInfections and infestations | 0/11 | 0/10 | 0/9 | 1/55 | 2/13 | 1/47 | 0/16 | 2/42 |
| Aphthous ulcerGastrointestinal disorders | 0/11 | 0/10 | 0/9 | 0/55 | 0/13 | 1/47 | 2/16 | 1/42 |
| Alanine aminotransferase increasedInvestigations | 0/11 | 0/10 | 0/9 | 2/55 | 1/13 | 0/47 | 2/16 | 2/42 |
All treated participants
| Age, Continuous(Years) | Placebo | BMS-986165 6 mg | BMS-986165 12 mg | Total |
|---|---|---|---|---|
| Mean | 48.5 ± 13.17 | 50.5 ± 13.69 | 50.5 ± 13.75 | 49.8 ± 13.51 |
| Sex: Female, Male(Participants) | Placebo | BMS-986165 6 mg | BMS-986165 12 mg | Total |
|---|---|---|---|---|
| Female | 40 | 30 | 34 | 104 |
| Male | 26 | 40 | 33 | 99 |
| Ethnicity (NIH/OMB)(Participants) | Placebo | BMS-986165 6 mg | BMS-986165 12 mg | Total |
|---|---|---|---|---|
| Hispanic or Latino | 7 | 4 | 5 | 16 |
| Not Hispanic or Latino | 59 | 65 | 62 | 186 |
| Unknown or Not Reported | 0 | 1 | 0 | 1 |
| Race (NIH/OMB)(Participants) | Placebo | BMS-986165 6 mg | BMS-986165 12 mg | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 1 | 3 | 0 | 4 |
| White | 65 | 67 | 67 | 199 |
| More than one race | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Apr 2019 to primary completion in Apr 2020, 12 months.
Results were first posted in May 2021, 1 year after primary completion.
Of 34 phase 2 interventional studies under Arthritis, Psoriatic, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 31. This study's 12 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Deucravacitinib · Ustekinumab